YUCAIPA, Calif., Feb. 12 Ingen Technologies,Inc. (OTC Bulletin Board: IGTG), a medical device manufacturer, announcedtoday the signed distribution agreement with Progressive International HoldingCo. LTD in Hong Kong to distribute Oxyview(R) in Taiwan, People's Republic ofChina, Japan and Korea. Please refer to the 8-K filing of this event.
Progressive International Holding Company (PIHK)(http://www.pgiholding.com) and its associate company, Progressive Group Inc(PGI), was founded in 1983 and is one of the major distributors of clinicaldiagnostic systems, medical devices and point of care products in Taiwan. Topursue the potential business opportunity in China and fully capitalize PGI'ssales & marketing experience of more than twenty years, PGI establishedProgressive International Holding Company (PIHK) in Hong Kong in 2005. PIHKhas tremendous synergy by utilizing the experience, expertise and connectionsof PGI in China and Taiwan to expand its product portfolio in patient oxygengas flow monitoring devices in the China, Japan and Korea markets.
The distribution agreement calls for a monthly minimum of 10,000Oxyview(R) units to be purchased by PIHK during a five year period. PIHK hassubmitted the application to the Chinese government agency known as SFDA forregistration of the free sales certificate.
"Ingen looks forward to working closely with Progressive. Julian Yuan, CEOof Progressive, visited our manufacturing facilities last year. Mr. Yuan isCEO of Aviva Biosciences in San Diego, California (http://www.avivabio.com),and has the resources to deliver Oxyview(R) to the Asian markets. Our companyis pleased to have the privilege of working with Progressive InternationalHolding Company," stated Scott Sand, Chairman and CEO of Ingen Technologies.
About Ingen Technologies, Inc.
Ingen Technologies, Inc., a Georgia Corporation, is a medical devicemanufacturer, certified through the Department of Health Services, and apublicly traded company trading under NASDAQ OTC: IGTG. The Company has beenin business since 1999. Ingen received FDA clearance last year and offersproducts for the respiratory markets. The Oxyview(R) and OxyAlert(R) areproprietary products that increase accuracy of medical care and preventunnecessary medical costs associated with today's healthcare industry. Ingenowns a variety of intellectual biotech property, including several USpatent(s) and several Foreign Patent(s) either issued or pending in the US,Japan, European Communities and People's Republic of China.
Safe Harbor for Forward-Looking Statements: This news release includesforward-looking statements. While these statements are made to convey to thepublic the company's progress, business opportunities and growth prospects,readers are cautioned that such forward-looking statements representmanagement's opinion. Whereas management believes such representations to betrue and accurate based on information and data available to the company atthis time, actual results may differ materially from those described. Thecompany's operations and business prospects are always subject to risk anduncertainties. Important factors that may cause actual results to differ areand will be set forth in the company's periodic filings with the U.S.Securities and Exchange Commission.For more information please visit:http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=igtg
SOURCE Ingen Technologies, Inc.